Form 4: Oruka Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Joana Goncalves, Chief Medical Officer of Oruka Therapeutics, Inc., sold 7,000 shares of common stock on August 17, 2026.
Summary
- Option exercise/conversion: acquired 3,500 Common Stock at $6.84 ($23,940) on August 17, 2026; holds 36,218 after (Direct).
- Option exercise/conversion: acquired 3,500 Common Stock at $7.80 ($27,300) on August 17, 2026; holds 39,718 after (Direct).
- Open-market sale: disposed of 900 Common Stock at $109.65 ($98,687) on August 17, 2026; holds 38,818 after (Direct).
- Open-market sale: disposed of 300 Common Stock at $110.52 ($33,155) on August 17, 2026; holds 38,518 after (Direct).
- Open-market sale: disposed of 3,320 Common Stock at $112.01 ($371,886) on August 17, 2026; holds 35,198 after (Direct).
- Open-market sale: disposed of 2,480 Common Stock at $112.56 ($279,154) on August 17, 2026; holds 32,718 after (Direct).
- Option exercise/conversion: disposed of 3,500 Employee Stock Option (right to buy) on August 17, 2026; holds 197,063 after (Direct).
- Option exercise/conversion: disposed of 3,500 Employee Warrant (right to buy) on August 17, 2026; holds 168,492 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $782,882 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Joana Goncalves — Officer (Chief Medical Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Option exercise/conversion | Common Stock | 3,500 | $7 | $23.9K | 36,218 |
| 2026-08-17 | Option exercise/conversion | Common Stock | 3,500 | $8 | $27.3K | 39,718 |
| 2026-08-17 | Open-market sale | Common Stock | 900 | $110 | $98.7K | 38,818 |
| 2026-08-17 | Open-market sale | Common Stock | 300 | $111 | $33.2K | 38,518 |
| 2026-08-17 | Open-market sale | Common Stock | 3,320 | $112 | $371.9K | 35,198 |
| 2026-08-17 | Open-market sale | Common Stock | 2,480 | $113 | $279.2K | 32,718 |
| 2026-08-17 | Option exercise/conversion | Employee Stock Option (right to buy) | 3,500 | — | — | 197,063 |
| 2026-08-17 | Option exercise/conversion | Employee Warrant (right to buy) | 3,500 | — | — | 168,492 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Option exercise/conversion (3,500 shares) |
| 2026-08-17 | Option exercise/conversion (3,500 shares) |
| 2026-08-17 | Open-market sale (900 shares) |
| 2026-08-17 | Open-market sale (300 shares) |
| 2026-08-17 | Open-market sale (3,320 shares) |
| 2026-08-17 | Open-market sale (2,480 shares) |
| 2026-08-17 | Option exercise/conversion (3,500 shares) |
| 2026-08-17 | Option exercise/conversion (3,500 shares) |
Keywords
insider transaction, Form 4, ORKA, Oruka Therapeutics, Inc., bearish, Joana Goncalves
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.